Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy (original) (raw)

• Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417.
  CAS Google Scholar
• Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251–2259.
  Article CAS Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260–2270.
  Article CAS Google Scholar
• le Coutre PD, Giles FJ, Hochhaus A, Apperley JF, Ossenkoppele GJ, Blakesley R et al. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia 2012; 26: 1189–1194.
  Article CAS Google Scholar
• Shami PJ, Deininger M . Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. Leukemia 2012; 26: 214–224.
  Article CAS Google Scholar
• Kantarjian H, Giles F, Wunderle L, Bhalla K, O’Brien S, Wassmann B et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542–2551.
  Article Google Scholar
• Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531–2541.
  Article CAS Google Scholar
• Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008; 22: 1200–1206.
  Article CAS Google Scholar
• Bixby D, Talpaz M . Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 2011; 25: 7–22.
  Article CAS Google Scholar
• Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007; 110: 4055–4063.
  Article CAS Google Scholar
• Hantschel O, Rix U, Schmidt U, Burckstummer T, Kneidinger M, Schutze G et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA 2007; 104: 13283–13288.
  Article CAS Google Scholar
• Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007; 25: 1035–1044.
  Article CAS Google Scholar
• Giles FJ, O’Dwyer M, Swords R . Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1698–1707.
  Article CAS Google Scholar
• Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R et al. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010; 116: 772–782.
  Article CAS Google Scholar
• Kreutzman A, Ladell K, Koechel C, Gostick E, Ekblom M, Stenke L et al. Expansion of highly differentiated CD8(+) T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia 2011; 25: 1587–1597.
  Article CAS Google Scholar
• Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009; 23: 1398–1405.
  Article CAS Google Scholar
• Nagata Y, Ohashi K, Fukuda S, Kamata N, Akiyama H, Sakamaki H . Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion. Int J Hematol 2010; 91: 799–807.
  Article Google Scholar
• Powers JJ, Dubovsky JA, Epling-Burnette PK, Moscinski L, Zhang L, Mustjoki S et al. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma 2011; 52: 668–679.
  Article CAS Google Scholar
• Valent JN, Schiffer CA . Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib. Leuk Res 2011; 35: e1–e3.
  Article Google Scholar
• Rohon P, Porkka K, Mustjoki S . Immunoprofiling of chronic myeloid leukemia patients at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol 2010; 85: 387–398.
  Article CAS Google Scholar
• Kim DH, Kamel-Reid S, Chang H, Sutherland R, Jung CW, Kim HJ et al. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 2009; 94: 135–139.
  Article CAS Google Scholar
• Porkka K, Koskenvesa P, Lundan T, Rimpilainen J, Mustjoki S, Smykla R et al. Dasatinib crosses the blood–brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008; 112: 1005–1012.
  Article CAS Google Scholar
• Bouchet S, Chauzit E, Ducint D, Castaing N, Canal-Raffin M, Moore N et al. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS. Clin Chim Acta 2011; 412: 1060–1067.
  Article CAS Google Scholar
• Ovaska K, Laakso M, Haapa-Paananen S, Louhimo R, Chen P, Aittomaki V et al. Large-scale data integration framework provides a comprehensive view on glioblastoma multiforme. Genome Med 2010; 2: 65.
  Article Google Scholar
• Koskinen K, Vainio PJ, Smith DJ, Pihlavisto M, Yla-Herttuala S, Jalkanen S et al. Granulocyte transmigration through the endothelium is regulated by the oxidase activity of vascular adhesion protein-1 (VAP-1). Blood 2004; 103: 3388–3395.
  Article CAS Google Scholar
• Salmi M, Koskinen K, Henttinen T, Elima K, Jalkanen S . CLEVER-1 mediates lymphocyte transmigration through vascular and lymphatic endothelium. Blood 2004; 104: 3849–3857.
  Article CAS Google Scholar
• Palani S, Maksimow M, Miiluniemi M, Auvinen K, Jalkanen S, Salmi M . Stabilin-1/CLEVER-1, a type 2 macrophage marker, is an adhesion and scavenging molecule on human placental macrophages. Eur J Immunol 2011; 41: 2052–2063.
  Article CAS Google Scholar
• Mustjoki S, Hernesniemi S, Rauhala A, Kahkonen M, Almqvist A, Lundan T et al. A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34). Haematologica 2009; 94: 1469–1471.
  Article CAS Google Scholar
• Luo FR, Yang Z, Camuso A, Smykla R, McGlinchey K, Fager K et al. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res 2006; 12: 7180–7186.
  Article CAS Google Scholar
• Lee SJ, Jung CW, Kim DY, Lee KH, Sohn SK, Kwak JY et al. Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia. Am J Hematol 2011; 86: 346–350.
  Article CAS Google Scholar
• Blake S, Hughes TP, Mayrhofer G, Lyons AB . The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol 2008; 127: 330–339.
  Article CAS Google Scholar
• Lee KC, Ouwehand I, Giannini AL, Thomas NS, Dibb NJ, Bijlmakers MJ . Lck is a key target of imatinib and dasatinib in T-cell activation. Leukemia 2010; 24: 896–900.
  Article CAS Google Scholar
• Salih J, Hilpert J, Placke T, Grunebach F, Steinle A, Salih HR et al. The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. Int J Cancer 2010; 127: 2119–2128.
  Article CAS Google Scholar
• Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011; 17: 1094–1100.
  Article CAS Google Scholar
• Yang Y, Liu C, Peng W, Lizee G, Overwijk WW, Liu Y et al. Anti-tumor T cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood 2012; 120: 4533–4543.
  Article CAS Google Scholar
• Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE . Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010; 116: 377–386.
  Article CAS Google Scholar
• Hennigs JK, Keller G, Baumann HJ, Honecker F, Kluge S, Bokemeyer C et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med 2011; 11: 30.
  Article CAS Google Scholar
• Quintas-Cardama A, Kantarjian H, O’Brien S, Borthakur G, Bruzzi J, Munden R et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007; 25: 3908–3914.
  Article CAS Google Scholar
• Cortes J, Kim DW, Raffoux E, Martinelli G, Ritchie E, Roy L et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008; 22: 2176–2183.
  Article CAS Google Scholar
• Danese S, de la Motte C, Reyes BM, Sans M, Levine AD, Fiocchi C . Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. J Immunol 2004; 172: 2011–2015.
  Article CAS Google Scholar
• Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR . Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol 2011; 29: 1039–1045.
  Article CAS Google Scholar
• Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011; 29: 1046–1051.
  Article CAS Google Scholar
• Kullander K, Klein R . Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 2002; 3: 475–486.
  Article CAS Google Scholar
• Poliakov A, Cotrina M, Wilkinson DG . Diverse roles of eph receptors and ephrins in the regulation of cell migration and tissue assembly. Dev Cell 2004; 7: 465–480.
  Article CAS Google Scholar
• Sharfe N, Nikolic M, Cimpeon L, Van De Kratts A, Freywald A, Roifman CM . EphA and ephrin-A proteins regulate integrin-mediated T lymphocyte interactions. Mol Immunol 2008; 45: 1208–1220.
  Article CAS Google Scholar
• Gleeson M, Bishop NC . The T cell and NK cell immune response to exercise. Ann Transplant 2005; 10: 43–48.
  PubMed Google Scholar
• Turner JE, Aldred S, Witard OC, Drayson MT, Moss PM, Bosch JA . Latent cytomegalovirus infection amplifies CD8 T-lymphocyte mobilisation and egress in response to exercise. Brain Behav Immun 2010; 24: 1362–1370.
  Article CAS Google Scholar
• Schedlowski M, Hosch W, Oberbeck R, Benschop RJ, Jacobs R, Raab HR et al. Catecholamines modulate human NK cell circulation and function via spleen-independent beta 2-adrenergic mechanisms. J Immunol 1996; 156: 93–99.
  CAS PubMed Google Scholar
• Dimitrov S, Lange T, Born J . Selective mobilization of cytotoxic leukocytes by epinephrine. J Immunol 2010; 184: 503–511.
  Article CAS Google Scholar
• Fan G, Shumay E, Malbon CC, Wang H . c-Src tyrosine kinase binds the beta 2-adrenergic receptor via phospho-Tyr-350, phosphorylates G-protein-linked receptor kinase 2, and mediates agonist-induced receptor desensitization. J Biol Chem 2001; 276: 13240–13247.
  Article CAS Google Scholar